Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Duffull

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pharmacy and Therapeutics|October 26, 2011
Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?A La Caze, S Duffull
Computer Methods and Programs in Biomedicine|March 29, 2001
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designsS Retout, S Duffull, F Mentré
Clinical Pharmacology and Therapeutics|May 18, 2007
Using disease progression models as a tool to detect drug effectD R Mould, N G Denman, S Duffull
Journal of Clinical Pharmacy and Therapeutics|October 18, 2002
Myocardial infarction and type II diabetes--preferential treatment for high risk patients?B Green, S Duffull, N Cottrell, et al.
Pharmaceutical Research|October 6, 2001
Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptanI Nestorov, G Graham, S Duffull, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pharmacy and Therapeutics|October 26, 2011
Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?A La Caze, S Duffull
Computer Methods and Programs in Biomedicine|March 29, 2001
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designsS Retout, S Duffull, F Mentré
Clinical Pharmacology and Therapeutics|May 18, 2007
Using disease progression models as a tool to detect drug effectD R Mould, N G Denman, S Duffull
Journal of Clinical Pharmacy and Therapeutics|October 18, 2002
Myocardial infarction and type II diabetes--preferential treatment for high risk patients?B Green, S Duffull, N Cottrell, et al.
Pharmaceutical Research|October 6, 2001
Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptanI Nestorov, G Graham, S Duffull, et al.
Pageof 1